TY - JOUR
T1 - Effects of α1-acid glycoprotein on erythrocyte deformability and membrane stabilization
AU - Matsumoto, Kazuaki
AU - Nishi, Katsuhide
AU - Tokutomi, Yoshiko
AU - Irie, Tetsumi
AU - Suenaga, Ayaka
AU - Otagiri, Masaki
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/1
Y1 - 2003/1
N2 - The effects of α1-acid glycoprotein (AGP) on human erythrocyte membrane were examined in vitro. Bovine and dog AGP, in addition to human AGP or asialo human AGP were used, and the collected data were compared with that for human serum albumin (HSA). A new technique developed by Kikuchi was used to investigate erythrocyte deformability. The addition of AGPs including human AGP facilitated the passage of human erythrocytes with an average diameter of 7.2 μm suspended in phosphate buffered saline (PBS) through a 5 μm wide microchannel; hemolysis was suppressed after the passage. The stabilizing effects of AGPs on membrane were evaluated. Human AGP prevented hemolysis induced by hypotonic phosphate buffer solution. The effects of human AGP on the oxidative changes in erythrocytes exposed to oxygen radicals were investigated. Human AGP protected erythrocytes from H2O2 and prevented the oxidation of dihydrorhodamine 123 to rhodamine 123 from H2O 2. We propose that the antioxidant activity of human AGP is due to the binding of free radicals. In all studies, the effects of human AGP on erythrocytes might not be a function of the negative charge associated with sialyl residues, because the presence of N-acetylneuraminic acid had no effect. However, human AGP may promote microcirculation and antioxidant activity compared with HSA. No species differences in the physiological function of AGP were found. These results suggest that an increase in the AGP content of serum above the normal value found under pathological conditions facilitates the passage of erythrocytes through capillaries, stabilizes erythrocyte membranes and protects against oxidative stress, all of which are favorable for microcirculation.
AB - The effects of α1-acid glycoprotein (AGP) on human erythrocyte membrane were examined in vitro. Bovine and dog AGP, in addition to human AGP or asialo human AGP were used, and the collected data were compared with that for human serum albumin (HSA). A new technique developed by Kikuchi was used to investigate erythrocyte deformability. The addition of AGPs including human AGP facilitated the passage of human erythrocytes with an average diameter of 7.2 μm suspended in phosphate buffered saline (PBS) through a 5 μm wide microchannel; hemolysis was suppressed after the passage. The stabilizing effects of AGPs on membrane were evaluated. Human AGP prevented hemolysis induced by hypotonic phosphate buffer solution. The effects of human AGP on the oxidative changes in erythrocytes exposed to oxygen radicals were investigated. Human AGP protected erythrocytes from H2O2 and prevented the oxidation of dihydrorhodamine 123 to rhodamine 123 from H2O 2. We propose that the antioxidant activity of human AGP is due to the binding of free radicals. In all studies, the effects of human AGP on erythrocytes might not be a function of the negative charge associated with sialyl residues, because the presence of N-acetylneuraminic acid had no effect. However, human AGP may promote microcirculation and antioxidant activity compared with HSA. No species differences in the physiological function of AGP were found. These results suggest that an increase in the AGP content of serum above the normal value found under pathological conditions facilitates the passage of erythrocytes through capillaries, stabilizes erythrocyte membranes and protects against oxidative stress, all of which are favorable for microcirculation.
KW - Antioxidant activity
KW - Erythrocyte osmotic fragility
KW - α-acid glycoprotein, erythrocyte deformability
UR - http://www.scopus.com/inward/record.url?scp=0037706816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037706816&partnerID=8YFLogxK
U2 - 10.1248/bpb.26.123
DO - 10.1248/bpb.26.123
M3 - Article
C2 - 12520190
AN - SCOPUS:0037706816
SN - 0918-6158
VL - 26
SP - 123
EP - 126
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 1
ER -